CY1122602T1 - Αντιμετωπιση των nafld και nash - Google Patents

Αντιμετωπιση των nafld και nash

Info

Publication number
CY1122602T1
CY1122602T1 CY20191101347T CY191101347T CY1122602T1 CY 1122602 T1 CY1122602 T1 CY 1122602T1 CY 20191101347 T CY20191101347 T CY 20191101347T CY 191101347 T CY191101347 T CY 191101347T CY 1122602 T1 CY1122602 T1 CY 1122602T1
Authority
CY
Cyprus
Prior art keywords
treatment
nafld
nash
mbx
salt
Prior art date
Application number
CY20191101347T
Other languages
English (en)
Inventor
Brian Roberts
Xueyan Wang
Yun-Jung Choi
David KARPF
Robert Martin
Charles A. Mcwherter
Original Assignee
Cymabay Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53373532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122602(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cymabay Therapeutics, Inc. filed Critical Cymabay Therapeutics, Inc.
Publication of CY1122602T1 publication Critical patent/CY1122602T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Αντιμετώπιση των NAFLD και NASH με θεραπεία με ΜΒΧ-8025 ή ένα άλας του ΜΒΧ-8025.
CY20191101347T 2014-04-11 2019-12-20 Αντιμετωπιση των nafld και nash CY1122602T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461978335P 2014-04-11 2014-04-11
PCT/US2015/025416 WO2015157697A1 (en) 2014-04-11 2015-04-10 Treatment of nafld and nash

Publications (1)

Publication Number Publication Date
CY1122602T1 true CY1122602T1 (el) 2021-03-12

Family

ID=53373532

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101347T CY1122602T1 (el) 2014-04-11 2019-12-20 Αντιμετωπιση των nafld και nash

Country Status (26)

Country Link
US (7) US9381181B2 (el)
EP (1) EP3129018B1 (el)
JP (1) JP6865038B2 (el)
KR (1) KR102374499B1 (el)
CN (1) CN106163508A (el)
AU (1) AU2015243239B2 (el)
BR (1) BR112016023269A8 (el)
CA (1) CA2944139C (el)
CL (1) CL2016002517A1 (el)
CY (1) CY1122602T1 (el)
DK (1) DK3129018T3 (el)
EA (1) EA036704B1 (el)
ES (1) ES2764467T3 (el)
HR (1) HRP20192299T1 (el)
IL (1) IL248193B (el)
LT (1) LT3129018T (el)
MX (1) MX369921B (el)
NZ (1) NZ724740A (el)
PH (1) PH12016501978A1 (el)
PL (1) PL3129018T3 (el)
PT (1) PT3129018T (el)
RS (1) RS59637B1 (el)
SG (1) SG11201608077PA (el)
SI (1) SI3129018T1 (el)
UA (1) UA121208C2 (el)
WO (1) WO2015157697A1 (el)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2334295T3 (en) 2008-09-02 2017-10-09 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME
CA2740874C (en) * 2008-10-17 2018-02-27 Metabolex, Inc. Use of ppar.gamma.agonists to reduce small dense ldl particles
MY198422A (en) 2009-04-29 2023-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
NZ627238A (en) 2009-04-29 2016-02-26 Amarin Pharmaceuticals Ie Ltd Stable pharmaceutical composition comprising ethyl eicosapentaenoate
MY172372A (en) 2009-06-15 2019-11-21 Amarin Pharmaceuticals Ie Ltd Compositions and methods for lowering triglycerides
RU2758369C2 (ru) 2009-09-23 2021-10-28 Амарин Фармасьютикалз Айрлэнд Лимитед Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина, и способы ее применения
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
US20140127289A1 (en) 2010-11-29 2014-05-08 Armarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
BR112014032905B1 (pt) 2012-06-29 2022-02-22 Amarin Pharmaceuticals Ireland Limited Uso de éster etílico do ácido eicosapentaenóico para redução do risco de morte cardiovascular, revascularização coronária e/ou angina instável em um indivíduo em terapia com estatina
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
ES2701094T3 (es) 2014-03-20 2019-02-20 Cymabay Therapeutics Inc Tratamiento de enfermedades colestáticas intrahepáticas
ES2764467T3 (es) 2014-04-11 2020-06-03 Cymabay Therapeutics Inc Tratamiento de NAFLD y NASH
EP3149156B1 (en) 2014-05-28 2021-02-17 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
US20180117013A1 (en) * 2015-03-26 2018-05-03 T3D Therapeutics, Inc. Methods of treating liver disease using indane acetic acid derivatives
ES2980790T3 (es) 2015-04-28 2024-10-03 Basf As Acidos grasos estructuralmente mejorados que contienen azufre para su uso en el tratamiento de la esteatohepatitis no alcohólica
WO2017049157A1 (en) 2015-09-18 2017-03-23 Duke University Methods and compositions for the treatment of steatosis-associated disorders
WO2017139708A1 (en) 2016-02-10 2017-08-17 Synlogic, Inc. Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US11066650B2 (en) 2016-05-05 2021-07-20 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
GB201614455D0 (en) 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
NZ753051A (en) 2016-11-04 2023-03-31 Children’S Hospital Medical Center Liver organoid compositions and methods of making and using same
US10493363B2 (en) * 2016-11-09 2019-12-03 Activision Publishing, Inc. Reality-based video game elements
US11767515B2 (en) 2016-12-05 2023-09-26 Children's Hospital Medical Center Colonic organoids and methods of making and using same
WO2018204775A1 (en) 2017-05-05 2018-11-08 Hepanova, Inc. Amino-aryl-benzamide compounds and methods of use thereof
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US20200276178A1 (en) 2017-09-13 2020-09-03 Novartis Ag Combinations comprising fxr agonists
JP6976030B2 (ja) * 2017-10-27 2021-12-01 サムヤン コーポレイション 非アルコール性脂肪肝疾患の予防または改善用組成物
CN111712240A (zh) 2017-12-06 2020-09-25 巴斯夫股份公司 用于治疗非酒精性脂肪性肝炎的脂肪酸衍生物
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
AU2019349563B2 (en) 2018-09-24 2023-06-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
BR112021009038A2 (pt) 2018-11-16 2021-08-10 Cymabay Therapeutics, Inc. tratamento combinado de nafld e nash
WO2020102351A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
WO2021097034A1 (en) * 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
US20210145774A1 (en) * 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
JP2023525571A (ja) * 2020-05-13 2023-06-16 ターンズ・ファーマシューティカルズ・インコーポレイテッド 肝障害の併用処置
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
WO2022238445A1 (en) * 2021-05-11 2022-11-17 Genfit Ppar-agonists for use in the treatment of liver failure

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
WO1996027606A1 (en) 1995-03-06 1996-09-12 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
CZ243498A3 (cs) 1996-02-14 1999-09-15 Isis Pharmaceuticals, Inc. Oligonukleotidy s mezerou a modifikovaným cukrem
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
EP1667964B1 (en) 2003-09-19 2009-07-22 Janssen Pharmaceutica N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
SI1725234T1 (sl) 2004-03-05 2013-04-30 The Trustees Of The University Of Pennsylvania Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih uäśinkov
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
US20080176861A1 (en) 2007-01-23 2008-07-24 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
CA2740874C (en) 2008-10-17 2018-02-27 Metabolex, Inc. Use of ppar.gamma.agonists to reduce small dense ldl particles
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
KR20160079124A (ko) 2013-11-20 2016-07-05 사이머베이 쎄라퓨틱스, 인코퍼레이티드 동질접합성 가족성 과콜레스테롤증의 치료
ES2701094T3 (es) 2014-03-20 2019-02-20 Cymabay Therapeutics Inc Tratamiento de enfermedades colestáticas intrahepáticas
ES2764467T3 (es) 2014-04-11 2020-06-03 Cymabay Therapeutics Inc Tratamiento de NAFLD y NASH
US20150374649A1 (en) 2014-06-26 2015-12-31 Cymabay Therapeutics, Inc Treatment of Severe Hypertriglyceridemia

Also Published As

Publication number Publication date
UA121208C2 (uk) 2020-04-27
US9616039B2 (en) 2017-04-11
US20190142776A1 (en) 2019-05-16
ES2764467T3 (es) 2020-06-03
US9962346B2 (en) 2018-05-08
US20150290154A1 (en) 2015-10-15
CA2944139A1 (en) 2015-10-15
EA201692050A1 (ru) 2017-01-30
JP6865038B2 (ja) 2021-04-28
SI3129018T1 (sl) 2020-02-28
DK3129018T3 (da) 2020-01-20
KR102374499B1 (ko) 2022-03-14
HRP20192299T1 (hr) 2020-03-06
MX2016013375A (es) 2017-02-15
BR112016023269A2 (pt) 2017-08-15
LT3129018T (lt) 2020-01-10
IL248193B (en) 2019-03-31
KR20160136451A (ko) 2016-11-29
EP3129018A1 (en) 2017-02-15
EP3129018B1 (en) 2019-10-23
CN106163508A (zh) 2016-11-23
US20200009092A1 (en) 2020-01-09
AU2015243239B2 (en) 2019-11-14
JP2017513836A (ja) 2017-06-01
US9381181B2 (en) 2016-07-05
US20160324812A1 (en) 2016-11-10
CL2016002517A1 (es) 2017-05-05
US20180228752A1 (en) 2018-08-16
RS59637B1 (sr) 2020-01-31
AU2015243239A1 (en) 2016-10-20
WO2015157697A1 (en) 2015-10-15
BR112016023269A8 (pt) 2021-06-29
US10342770B2 (en) 2019-07-09
US20210038546A1 (en) 2021-02-11
NZ724740A (en) 2019-11-29
SG11201608077PA (en) 2016-10-28
MX369921B (es) 2019-11-26
PT3129018T (pt) 2020-01-15
US20180008566A1 (en) 2018-01-11
PH12016501978A1 (en) 2016-12-19
EA036704B1 (ru) 2020-12-10
US11179359B2 (en) 2021-11-23
US10722483B2 (en) 2020-07-28
CA2944139C (en) 2020-11-03
PL3129018T3 (pl) 2020-05-18
US10188620B2 (en) 2019-01-29

Similar Documents

Publication Publication Date Title
CY1122602T1 (el) Αντιμετωπιση των nafld και nash
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
DK3506854T3 (da) Brystbehandlingsindretning
DK3212670T3 (da) Kombinationsterapi mod cancer
DK3469425T3 (da) Strålingskilde
ECSP17015977A (es) Terapia de combinacion
DK3283527T3 (da) Kombinationsterapi mod cancer
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
DK3423087T3 (da) Kombinationsterapi mod cancer
MA39483A (fr) Agents thérapeutiques cibles
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CY1123019T1 (el) Σπειροκυκλικες ενωσεις
DK3468496T3 (da) Elektrokirurgisk indretning med integreret mikrobølgekilde
DK3215607T3 (da) Phagterapi
DK3393478T3 (da) Kombinationsterapi
EA201691887A1 (ru) Лечение внутрипеченочных холестатических заболеваний
DK3408265T3 (da) Terapeutiske forbindelser
DK3688530T3 (da) Strålingskilde
DK3576740T3 (da) Cancerbehandling
DK3188599T3 (da) Medicinske behandlinger baseret på anamorelin
DK3302478T3 (da) Pac-1 kombinations behandling
DK3407909T5 (da) Cancerbehandling
CL2016002892A1 (es) Anticuerpos ang2
DK3122375T3 (da) Vacciner mod bryst- og ovariecancer
DE112015001144A5 (de) Therapievorrichtung